[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX339878B - Nuevas formas solidas de clorhidrato de bendamustina. - Google Patents

Nuevas formas solidas de clorhidrato de bendamustina.

Info

Publication number
MX339878B
MX339878B MX2013011045A MX2013011045A MX339878B MX 339878 B MX339878 B MX 339878B MX 2013011045 A MX2013011045 A MX 2013011045A MX 2013011045 A MX2013011045 A MX 2013011045A MX 339878 B MX339878 B MX 339878B
Authority
MX
Mexico
Prior art keywords
solid forms
novel solid
bendamustine hydrochloride
bendamustine
hydrochloride
Prior art date
Application number
MX2013011045A
Other languages
English (en)
Inventor
Martin Ian Cooper
Laurent D Courvoisier
Mark Eddleston
Robert E Mckean
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX339878(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX339878B publication Critical patent/MX339878B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen nuevas formas sólidas de clorhidrato de bendamustina, al igual que métodos para su preparación y uso.
MX2013011045A 2008-03-26 2009-03-26 Nuevas formas solidas de clorhidrato de bendamustina. MX339878B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3975208P 2008-03-26 2008-03-26
PCT/US2009/001956 WO2009120386A2 (en) 2008-03-26 2009-03-26 Novel solid forms of bendamustine hydrochloride

Publications (1)

Publication Number Publication Date
MX339878B true MX339878B (es) 2016-06-15

Family

ID=41051023

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010010398A MX2010010398A (es) 2008-03-26 2009-03-26 Nuevas formas solidas de clorhidrato de bendamustina.
MX2013011045A MX339878B (es) 2008-03-26 2009-03-26 Nuevas formas solidas de clorhidrato de bendamustina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010010398A MX2010010398A (es) 2008-03-26 2009-03-26 Nuevas formas solidas de clorhidrato de bendamustina.

Country Status (12)

Country Link
US (9) US20090264488A1 (es)
EP (2) EP3150197A1 (es)
JP (1) JP5536753B2 (es)
CN (3) CN105693620A (es)
AR (1) AR072777A1 (es)
CA (1) CA2718939A1 (es)
CL (1) CL2009000742A1 (es)
ES (1) ES2605205T3 (es)
HK (1) HK1220966A1 (es)
MX (2) MX2010010398A (es)
TW (1) TWI472515B (es)
WO (1) WO2009120386A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
ES2583804T3 (es) * 2007-10-09 2016-09-22 Us Worldmeds Llc Composiciones de codisolventes y métodos para la administración mejorada de agentes terapéuticos de dantroleno
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2326306A1 (en) 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
WO2010144675A1 (en) * 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
WO2011079193A2 (en) * 2009-12-23 2011-06-30 Dr. Reddy's Laboratories Ltd. Preparation of bendamustine and its salts
HUE031208T2 (hu) 2010-01-28 2017-07-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
KR101830142B1 (ko) 2010-06-02 2018-02-20 아스텔라스 도이칠란트 게엠베하 벤다무스틴의 경구 투약 형태
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN101948437B (zh) * 2010-06-28 2012-08-29 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀的精制方法
WO2012059935A1 (en) 2010-11-01 2012-05-10 Shilpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
US20140142153A1 (en) * 2011-01-25 2014-05-22 Dr. Reddy's Laboratories, Inc. Bendamustine formulations
AU2012212622A1 (en) * 2011-01-31 2013-07-11 Cephalon, Inc. Methods for the preparation of bendamustine
WO2013046223A1 (en) 2011-09-26 2013-04-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of bendamustine hydrochloride
CN102351799B (zh) * 2011-10-24 2014-02-26 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀晶型及其制备方法
EP2617716A1 (en) 2012-01-18 2013-07-24 Arevipharma GmbH Process for the preparation of bendamustine hydrochloride and related compounds
WO2013142359A1 (en) 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
CN104302291A (zh) 2012-03-20 2015-01-21 鹰制药股份有限公司 苯达莫司汀的制剂
WO2013150020A1 (en) 2012-04-03 2013-10-10 Synthon Bv Process for making bendamustine
PT2656843E (pt) 2012-04-26 2015-04-14 Helmut Schickaneder Ésteres de bendamustina e compostos relacionados e a sua utilização médica
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9801859B2 (en) * 2012-09-18 2017-10-31 Innopharma Licensing, Llc Bendamustine formulations
WO2014075035A1 (en) 2012-11-12 2014-05-15 Cephalon, Inc. Bendamustine derivatives and methods of using same
WO2014127802A1 (en) 2013-02-19 2014-08-28 Synthon Bv Stable compositions of bendamustine
US9315469B2 (en) 2013-03-14 2016-04-19 Johnson Matthey Public Limited Company Process for drying bendamustine hydrochloride monohydrate
WO2014170769A2 (en) * 2013-04-15 2014-10-23 Shilpa Medicare Limited Bendamustine lyophilized pharmaceutical compositions
US9849115B2 (en) 2013-08-27 2017-12-26 Vasilios Voudouris Bendamustine pharmaceutical compositions
EP3116481A1 (en) 2014-03-13 2017-01-18 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
EP2985038A1 (en) 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
JP6616431B2 (ja) * 2015-06-09 2019-12-04 レビオティクス インコーポレイテッド マイクロバイオータ回復治療（ｍｒｔ）組成物の製造方法
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
WO2019068904A1 (en) 2017-10-05 2019-04-11 Tube Pharmaceuticals Gmbh ORAL ADMINISTRATION OF BENDAMUSTINE FORMULATIONS
CN111093654B (zh) * 2017-11-07 2023-03-10 江苏恒瑞医药股份有限公司 一种盐酸苯达莫司汀的晶体及其制备方法
EA037673B1 (ru) * 2018-07-04 2021-04-29 Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4419147A1 (en) 2021-10-22 2024-08-28 Project Pharmaceutics GmbH Liquid pharmaceutical formulation

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (es)
DE159877C (es) *
DD80967A (es)
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
DE159289C (es) 1903-10-08 1905-03-16
DE293808C (es)
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5227374A (en) 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US4659699A (en) 1983-08-22 1987-04-21 Cetus-Ben Venue Therapeutics Process for freeze drying cyclophosphamide
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
DE58900183D1 (de) 1988-03-19 1991-08-29 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
DE3907079A1 (de) 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
US5036060A (en) 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2001552C (en) 1988-11-14 1997-07-22 The Upjohn Company Cyclophosphamide - sodium bicarbonate lyophilizates
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
US5051257A (en) 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
DD293808A5 (de) 1990-04-23 1991-09-12 Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern
US5268368A (en) 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
PT752248E (pt) * 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5418223A (en) 1993-05-20 1995-05-23 Erbamont, Inc. Method for lyophilization of cyclophosphamide and product
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
AU688792B2 (en) * 1993-10-27 1998-03-19 Pharmacia & Upjohn Company Stabilized prostaglandin e1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
WO1997008174A1 (en) 1995-08-31 1997-03-06 Smithkline Beecham Corporation Interleukin converting enzyme and apoptosis
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
EA200000087A1 (ru) 1997-07-01 2000-08-28 Атеродженикс, Инк. Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
PT1104297E (pt) * 1998-07-09 2006-05-31 Cephalon Inc Composicoes para o tratamento da leucemia linfocitica cronica
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
EP1350793A1 (en) * 2000-12-11 2003-10-08 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
CN1487935A (zh) * 2000-12-11 2004-04-07 ����ҩƷ��ҵ��ʽ���� 改良型水溶性药物组合物
WO2002080996A1 (de) * 2001-04-03 2002-10-17 Franz Herbst Medizinisches implantat und verfahren zu seiner herstellung
CA2462723C (en) * 2001-10-15 2012-05-01 Hemoteq Gmbh Coated stents for preventing restenosis
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
JP4443935B2 (ja) 2002-03-22 2010-03-31 ルートヴィヒ マクシミリアン ウニヴェルジテート 高用量細胞傷害性化学療法後の造血回復、好中球減少性発熱、および抗菌処置の予測のための細胞能力試験
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
CA2484269C (en) * 2002-05-09 2012-01-17 Hemoteq Gmbh Compounds and method for coating surfaces in a haemocompatible manner
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US20040151774A1 (en) 2002-10-31 2004-08-05 Pauletti Giovanni M. Therapeutic compositions for drug delivery to and through covering epithelia
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
TW200427463A (en) * 2003-02-14 2004-12-16 Salmedix Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
JP2007500191A (ja) * 2003-07-25 2007-01-11 ワイス Ｃｃｉ−７７９の凍結乾燥処方
AR054094A1 (es) 2004-11-05 2007-06-06 Cephalon Inc Tratamientos de cancer
CN101060832A (zh) 2004-11-22 2007-10-24 维纳斯药业有限公司 非水液体肠胃外醋氯芬酸配方
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
WO2006110551A2 (en) 2005-04-08 2006-10-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ITUD20070130A1 (it) 2007-07-23 2009-01-24 C M E Spa Sa Macchina e procedimento per la produzione di elementi strutturali per l'edilizia in materiale cementizio aventi uno o piu' inserti in materiale polimerico
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2326306A1 (en) 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
CA2760085A1 (en) 2009-04-28 2010-11-04 Cephalon, Inc. Oral formulations of bendamustine

Also Published As

Publication number Publication date
US8883836B2 (en) 2014-11-11
EP3150197A1 (en) 2017-04-05
US9533955B2 (en) 2017-01-03
US20090264488A1 (en) 2009-10-22
CN101980698A (zh) 2011-02-23
US10039750B2 (en) 2018-08-07
US20140187598A1 (en) 2014-07-03
AR072777A1 (es) 2010-09-22
WO2009120386A2 (en) 2009-10-01
TW200944508A (en) 2009-11-01
US20200323824A1 (en) 2020-10-15
CL2009000742A1 (es) 2009-11-13
ES2605205T3 (es) 2017-03-13
HK1220966A1 (zh) 2017-05-19
JP5536753B2 (ja) 2014-07-02
WO2009120386A3 (en) 2009-12-03
CN101980698B (zh) 2013-10-16
US20160159748A1 (en) 2016-06-09
US20150051258A1 (en) 2015-02-19
US8669279B2 (en) 2014-03-11
US20130245086A1 (en) 2013-09-19
US20170071913A1 (en) 2017-03-16
US8445524B2 (en) 2013-05-21
US20190015390A1 (en) 2019-01-17
US20120071532A1 (en) 2012-03-22
EP2271315A2 (en) 2011-01-12
CN103550159A (zh) 2014-02-05
CN105693620A (zh) 2016-06-22
TWI472515B (zh) 2015-02-11
CA2718939A1 (en) 2009-10-01
US10517852B2 (en) 2019-12-31
JP2011515472A (ja) 2011-05-19
CN103550159B (zh) 2016-02-10
MX2010010398A (es) 2010-12-20
EP2271315B1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
MX339878B (es) Nuevas formas solidas de clorhidrato de bendamustina.
MX2012007507A (es) Compuestos de heteroarilo y usos de los mismos.
MY181898A (en) Heterocyclic compounds and uses thereof
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
EP2248171A4 (en) SEMICONDUCTOR CONSTRUCTIONS AND METHODS OF FORMING SEMICONDUCTOR CONSTRUCTIONS
RS53124B (en) USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY
MY158992A (en) Forms of rifaximin and uses thereof
TN2011000673A1 (en) Bace inhibitors
BR112012000735A2 (pt) "métodos, kits e conjuntos de compostos"
EP2437602A4 (en) OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
ZA201203603B (en) Lyophilization methods, compositions, and kits
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
EP2238451A4 (en) NANOSTRUCTURES, METHODS OF PREPARATION AND USES THEREOF
IL208613A (en) Aztidine derivatives, methods of preparation, preparations containing them and their use
MX2013002784A (es) Heteroarilos fusionados y sus usos.
MY161601A (en) Films and compositions comprising the same
EP2245113A4 (en) PHOSPHORESCENT COMPOSITIONS, METHODS FOR PREPARING THE COMPOSITIONS, AND METHODS OF USING THE COMPOSITIONS
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
EP2289104A4 (en) DIODES AND METHOD FOR FORMING DIODES
IN2012DN03404A (es)
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
MX2011010046A (es) Derivados de diaminopteridina.
EP2350212A4 (en) POLYAMINO-ACETONITRILES, PROCESSES FOR PREPARING THEM AND USE THEREOF
WO2010004512A3 (en) Dicarba-analgues of octreotide
MX2013008559A (es) Derivados de leptina.